Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles

Chuan Shih, Ph.D.

Distinguished Investigator
Institute of Biotechnology and Pharmaceutical Research


• Postdoctoral Fellow, Nobel Laureate, Professor Elias J. Corey, Harvard University, Cambridge, Massachusetts, USA (1982-1984)
• Ph.D., Synthetic Organic Chemistry, The Ohio State University, Columbus, Ohio, USA(1982)
• M.S., Organic Chemistry, The Ohio State University, Columbus, Ohio, USA (1979)
• B.S., Chemistry, National Chung-Hsing University, Taichung, Taiwan (1976)


Distinguished Investigator and Director, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan (2014-present)
Chief Scientific Officer and Executive Vice President, Integrated Drug Discovery Operation, Crown Bioscience Inc. (2010-2014)
Distinguished Chair Professor, Department of Applied Biology and Chemical Technologies, Hong Kong Polytechnic University (2009-2010)
Distinguished Lilly Scholar (2007-2009)
* Distinguished Lilly Scholar is the highest rank position in scientific track of LRL (Lilly Research Laboratories), equivalent to Vice President in Lilly??s R/D organization
Distinguished Research Fellow, Lilly Research Laboratories (2004-2007)
Research Fellow, Lilly Research Laboratories (1999-2004)
Senior Research Scientist, Lilly Research Laboratories (1993-1998)
Research Scientist, Lilly Research Laboratories (1989-1992)
Senior Organic Chemist, Lilly Research Laboratories (1984-1988)


Dr. Shih's interest covers a broad range of drug discovery & development. From the beginning stage of synthetic chemistry, lead identification and lead optimization, to the later stages such as in vitro/in vivo pharmacology, drug metabolism and preformulation. His area of interest in oncology is vast: from cyctotosic agents such as lometrexol and pemetrexed (Alimta®), to targeted therapeutic agents.


1.Robert M. Campbell, Bryan D. Anderson, Nathan A Brooks, Harold B. Brooks, Edward M. Chan, Alfonso De Dios, Raymond Gilmour, Jeremy Graff, Enrique Jambrina, Mary Mader, Denis McCann, Songqing Na, Stephen Parsons, Susan Pratt, Chuan Shih, Louis F. Stancato, James J. Starling, Courtney Tate, Juan A. Velasco, Yong Wang, Xiang Ye, Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with anti-tumor activity, Molecular Cancer Therapeutics, (submitted for publication) 2013
2.S. Betty Yan, Victoria L. Peek, Rose Ajamie,
Sean G. Buchanan, Jeremy R. Graff,
Steven A. Heidler, Yu-Hua Hui, Karen L. Huss, Bruce W. Konicek, Jason R. Manro, Chuan Shih, Julie A. Stewart, Trent R. Stewart, Stephanie L. Stout, Mark T. Uhlik, Suzane L. Um, Yong Wang, Wenjuan Wu, Lei Yan, Wei J. Yang, Boyu Zhong and Richard A. Walgren, LY2801653 is an orally bioavailable multi-kinase inhibitor
with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs (2013) 31:833?V844.
3.Mader, Mary; de Dios, Alfonso; Shih, Chuan; Bonjouklian, Rosanne; Li, Tiechao; White, Wesley; Lopez de Uralde, Beatriz; Sanchez-Martinez, Concepcion; del Prado, Miriam; Jaramillo, Carlos; de Diego, Eugenio; Martin Cabrejas, Luisa M.; Dominguez, Carmen; Montero, Carlos; Shepherd, Timothy; Dally, Robert; Toth, John E.; Chatterjee, Arindam; Pleite, Sehila; Blanco-Urgoiti, Jaime; Perez, Leticia; Barberis, Mario; Lorite, Maria Jose; Jambrina, Enrique; Nevill, C. Richard; Lee, Paul A.; Schultz, Richard C.; Wolos, Jeffrey A.; Li, Li C.; Campbell, Robert M.; Anderson, Bryan D., Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38 MAP kinase inhibitors with excellent in vivo antiinflammatory properties., Bioorganic & Medicinal Chemistry Letters (2008), 18(1), 179-183.
4.Ishitsuka, Kenji; Hideshima, Teru; Neri, Paola; Vallet, Sonia; Shiraishi, Norihiko; Okawa, Yutaka; Shen, Zhenxin; Raje, Noopur; Kiziltepe, Tanyel; Ocio, Enrique M.; Chauhan, Dharminder; Tassone, Pierfrancesco; Munshi, Nikhil; Campbell, Robert M.; de Dios, Alfonso; Shih, Chuan; Starling, James J.; Tamura, Kazuo; Anderson, Kenneth C., p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications, British Journal of Haematology (2008), 141(5), 598-606


1.N-(Pyrrolo[2,3-D]Pyr Imidin-3-ylacyl)-Glutamic Acid Derivatives, Shih Chuan, Kuhnt Dietmar G, Grindey Gerald Burr, Taylor Edward Curtis, US Patent, 4996206, 26 February, 1991
2.Pyrrolo[2,3-D]Pyrimidines, Shih Chuan, Kuhnt Dietmar G, Taylor Edward Curtis, Grindey Gerald Burr, US Patent, 5248775, 28 September, 1993
3.DDATHF Folic Acid Combination, Shih Chuan, Grindey Gerald Burr, US Patent, 5217974, 08, June, 1993
4.DDATHF Folic Acid Combination, Shih Chuan, Grindey Gerald Burr, European Patent 0505640, 23, August, 1995
5.Cryptophycin compounds, Al-Awar; Rima S; Ehlhardt; William J; Gottumukkala; Subbaraju V; Martinelli; Michael J; Moher; Eric D; Moore; Richard E; Munroe; John E; Norman; Bryan H; Patel; Vinod F; Ray; James E; Shih; Chuan; Toth; John E; Vasudevan; Venkatraghavan, US Patent, 6680311, 20, January, 2004
6.Preparation of imidazo-pyridine derivatives as p38 kinase inhibitors, Bonjouklian, Rosanne; Hamdouchi, Chafiq Hamdouchi; Shih, Chuan; De Dios, Alfonso; Del Prado, Miriam Filadelfa; Jaramillo Aguado, Carlos; Kotiyan, Pramila; Mader, Mary Margaret; Selgas, Sheila Pleite; Sanchez-Martinez, Concepcion, PCT Int. Appl. (2005), 76 pp.CODEN: PIXXD2 WO 2005075478 A1 20050818